Personal tumor vaccine for melanoma and soft tissue sarcoma
Part of Cancer, Skin clinical trials.
This trial tests a personalized vaccine made from your own tumor tissue. The goal is to help your immune system fight cancer and to improve the response to PD-1 inhibitor therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have melanoma or soft tissue sarcoma that has progressed after standard treatment or after PD-1 inhibitor therapy.
- You are generally well enough to be up and about (ECOG performance status 0-2).
- Your blood counts and kidney/liver function are within the required ranges.
- You have a tumor that can be biopsied or surgically removed for vaccine preparation.
- You are not pregnant, and you agree to use effective birth control during the study and for 4 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cancer vaccine for people with certain cancers (bladder, stomach/esophagus, melanoma, or lung) who have no visible cancer after surgery but still have tiny bits of cancer DNA in their blood (called MRD). The vaccine is designed to train your immune system to attack any remaining cancer cells.
This trial tests a personalized vaccine made from your own tumor material, aiming to lower the chance cancer returns after surgery. It is for people whose rare cancers have been removed completely and who have no standard treatment available after surgery.
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
This study tests a personalized vaccine made from your tumor's unique mutations, combined with special immune cells grown from your blood, to treat advanced sarcoma (bone or soft tissue cancer) that did not respond to initial treatment. The goal is to help your immune system recognize and attack cancer cells.
This trial tests a personalized mRNA cancer vaccine (RH125) for people with advanced solid tumors that have spread or cannot be removed by surgery. It may be an option if standard treatments have stopped working or are not suitable, and for some, it will be given with a PD-1 blocker.
This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.